drugset / Trial / NCT02791906
Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease
RandomizedParallel-groupOpen-labelOther
Summary
Heart failure (HF) is an epidemic and is a major burden on the US healthcare system. The most common cardiovascular endpoint is HF. Thus, novel interventions to prevent HF in chronic kidney disease (CKD) are highly desirable. This study will assess: the variability in the response to isosorbide mononitrate (ISMN) therapy; the degree of change in central hemodynamics and cardiac endpoints through analysis of changes in left ventricle (LV) mass, diffuse myocardial fibrosis, and myocardial systolic and diastolic function.
Timeline
- Start
- 2016-05
- Primary completion
- 2019-03
- Completion
- 2019-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isosorbide Mononitrate | Other / unclassified | 60 mg | — |
| Subject | Isosorbide Mononitrate | Other / unclassified | 120 mg | — |